Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms
Sponsor: Bir Hospital
Summary
A comparative study on the efficacy of Tamsulosin, Solifenacin and Mirabegron in alleviating ureteral stent-related symptoms: a randomized controlled trial.
Official title: A Comparative Study on the Efficacy of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms: a Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
189
Start Date
2025-08-30
Completion Date
2026-12-31
Last Updated
2025-09-08
Healthy Volunteers
No
Conditions
Interventions
Tamsulosin Hydrochloride 0.4 mg
placement of ureteral stents followed by Cap. Tamsulosin 0.4 mg once daily
Solifenacin Succinate 5 mg
placement of ureteral stents followed by Tab. Solifenacin 5 mg once daily
Mirabegron 25 mg
placement of ureteral stents followed by Tab. Mirabegron 25 mg once daily
Locations (1)
NAMS, Bir Hospital
Kathmandu, Bagmati, Nepal